Approach to critical illness polyneuropathy and myopathy

Postgraduate Medical Journal

Volumn 84, Issue 993, 2008, Pages 354-360

  Pati, S ^a   Goodfellow, J A ^a   Iyadurai, S ^a   Hilton Jones, D ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; IMMUNOGLOBULIN; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NEUROMUSCULAR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL FEATURE; CRITICAL ILLNESS; ELECTROMYOGRAM; ELECTRONYSTAGMOGRAPHY; HUMAN; INTENSIVE CARE; MUSCLE BIOPSY; MUSCLE CELL; MYOPATHY; OUTCOME ASSESSMENT; PATHOGENESIS; PHYSIOTHERAPY; PLASMAPHERESIS; POLYNEUROPATHY; REVIEW; RISK FACTOR; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

HUMANS; MUSCULAR DISEASES; POLYNEUROPATHIES; TREATMENT OUTCOME;

EID: 50249142539     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.064915     Document Type: Review

References (46)

1. MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. Lancet 1977;2:615.
2. Stevens RD, Dowdy DW, Michaels RK, et al. Neuromuscular dysfunction acquired in critical care illness: a systematic review. Intensive Care Med 2007;33:1876-91.
3. Latronico N, Bertolini G, Guameri B, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care 2007;11:R11.
4. Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve 1998;21:610-17.
5. Oe Jonghe B, Sharshar T, Lefaucher JP, et al, Groupe do Reflexion et d'Etude des Neuromyopathies en Reanimation. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002;288:2859-67.
6. Laijten FS, de Weerd AW, Poortvliet DC, et al. Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med 1996;22:856-61.
7. Garnacho-Montero J, Madrazo-Osuna J, García-Garmendia JL, et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med 2001;27:1288-96.
8. Bolton CF. Neuromuscular complications of sepsis. Intensive Care Med 1993;19:S58-63.
9. Da Letter MA, Schmitz PI, Visser FA, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001;29:2281-6.
10. Witt NJ, Zochodne DW, Bolton CF, et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991;99:176- 84.
11. Druschky A, Herkert M, Radespiel-Troger M, et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 2001;27:686-93.
12. Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet 1996;347:1579-82.
13. Bolton CF, Gilbert JJ, Hahn AF, et al. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984;47:1223-31.
14. Zochodne DW, Bolton CF, Wells GA, et al. Critical illness polyneuropathy. Brain 1987;110:819-42.
15. Bird SJ. Diagnosis and management of critical illness polyneuropathy and critical illness myopathy. Current Treatment Options in Neurology 2007;9:85-92.
16. Bolton CF. Critical illness polyneuropathy. In: Thomas PK, Asbury A, eds. Peripheral nerve disorders II. Oxford: Butterworth-Heinemann, 1995:262-70.
17. Coakley JH, Nagendran K, Yarwood GD, et al. Patterns of neurophysiological abnormality in prolonged critical illness. Intensive Care Med 1998;24:801-7.
18. Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996;24:1408-16.
19. Bednarik J, Vondracek P, Dusek L, et al. Risk factors for critical illness polyneuromyopathy. J Neurol 2005;252:343-51.
20. Bolton CF. Electrophysiologic studies of critically ill patients. Muscle Nerve 1987;10:129-35.
21. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
22. Van der Schaaf M, Beelen A, de Groot IJ. Critical illness polyneuropathy: a summary of the literature on rehabilitation outcome. Disabil Rehabil 2000;22:808-10.
23. Leijten FS, Harinck-de Weerd JE, Poortvliet DC, et al. The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA 1995;274:1221-5.
24. Bumham EL, Moss M, Ziegler TR. Myopathies in critical illness: characterisation and nutritional aspects. J Nutr 2005;135:1818S- 23S.
25. Mesotten D, Swinnen JV, Vanderhoydonc F, et al. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocinol Metab 2004;89:219-26.
26. Wijdicks EF, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve 1994;17:1494-5.
27. Lowry SF. Sepsis and its complications: clinical definitions and therapeutic prospects. Crit Care Med 1994;22:S1-2.
28. Spies CD, Reinhart K. Witt I, et al. influnce of N-acetylcysteine on irdirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit Care Med 1994;22:1738-46.
29. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005;32:140-63.
30. Osier W. The principles and practice of medicine. New York: D Appleton, 1892.
31. Hund E. Myopathy in critically ill patients. Crit Care Med 1999;27:2544-7.
32. Fragher MW, Day BJ, Dennett X. Critical care myopathy: an electrophysiological and histological study. Muscle Nerve 1996;19:516-18.
33. Douglass JA, Tuxen DV, Home M, et al. Myopathy in severe asthma. Am Rev Respir Dis 1992;146:517-19.
34. Lacomis D, Giuliani MJ, Van Cott A, et al. Acute myopathy of intensive care: clinical. EMG, and pathologic aspects. Ann Neurol 1996;40:645-54.
35. Latronico N. Neuromuscular alterations in the critically ill patient: critical illness myopathy, critical illness neuropathy, or both? Intensive Care Med 2003,24:1411-13.
36. Lefaucheur JP, Nordine T, Rodriguez P, et al. Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry 2006;77:500-6.
37. Latronico N, Candiani A. Muscular wasting as a consequence of sepsis. In: Gullo A. ed. Anaesthesia, pain, intensive care and emergency medicine, A.P.I.C.E. Milan: Springer Italia, 1998;13:517-22.
38. Novak F, Heyland DK, Avenell A, et al. Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med 2002;30:2022-9.
39. Lemaira F. Difficult weaning. Intensive Care Med 1993;19:S69-73.
40. Lacomis D, Giuliani MJ, Van Cott A, et al. Acute myopathy of intensive care: clinical. EMG, and pathologic aspects. Ann Neurol 1996;40:645-54.
41. Fletcher SN, Kennedy DD. Ghosh IR, et al. Persistent neuromuscular and neurophysiology abnormalities in long-term survivors of critical illness. Crit Care Med 2003;31:1012-16.
42. Maramattom BV, Wijdicks EF. Acute neuromuscular weakness in the intensive care unit. Crit Med Care 2006;34:2835-41.
43. Latronico N, Bertolini G. Guarneri B, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care 2007;11:R11.
44. Stibler H, Edstrom L, Ahlbeck K, et al. Electrophoretic determination of the myosin/ actin ratio in the diagnosis of critical illness myopathy. Intensive Care Med 2003;29:1515-27.
45. Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997;23:1144-9.
46. Feasby T, BanwellB, Benstead T. et al. Guioelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007;21(2 Suppl 1):S57-107.